logo
Plus   Neg
Share
Email

Aerpio Pharma: TIME-2b Study With AKB-9778 Fails To Meet Primary Endpoint

Aerpio Pharmaceuticals, Inc. (ARPO) announced top-line results from the company's TIME-2b study, a Phase 2b clinical trial designed to assess the efficacy and safety of lead candidate, AKB-9778, for patients with moderate to severe non-proliferative diabetic retinopathy. The company said the administration of AKB-9778 twice daily did not meet the study's primary endpoint of the percentage of patients with an improvement of two or more steps in the study eye diabetic retinopathy severity score compared to placebo.

AKB-9778 did show encouraging data in a number of prespecified, key secondary endpoints, consistent with the observations in the prior Phase 2a trial, the company noted. AKB-9778 was found to be safe and well-tolerated in the patient population through 48 weeks of twice-daily dosing.

"While we are disappointed in the primary endpoint results of this study, we are nevertheless encouraged by the fact that several other promising findings observed in our prior 3-month Phase 2a trial have been prospectively confirmed in this 1-year trial. We and our clinical advisors believe that collectively these data support a potentially important role of the Tie2 pathway for the treatment of diabetic complications, as well as for open angle glaucoma. After a full analysis of the study data, we plan to provide an update on the status of the NPDR program," said Stephen Hoffman, CEO of Aerpio.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Shares of Stage Stores, Inc. (SSI) hit a new 52-week high of $6.74 today, which is a giant leap forward for a stock that was perilously close to delisting just a few months ago. The stock has been experiencing positive momentum, after raising expectations for fiscal 2019. Amazon founder and Chief Executive Jeff Bezos said his company will continue to support the U.S. Department of Defense, noting that the U.S. will be in "big trouble" if big technology companies stop working with the Pentagon. "We are going to support the Department of Defense, this country is important," Bezos said at the annual Reagan National Defense Forum in Simi Valley, California. Surly Bikes recalled 5,139 units of Surly front bicycle racks for possible crash and injury hazards, a statement by the U.S. Consumer Product Safety Commission showed. The company said the front bicycle rack can loosen and contact the front wheel, resulting in crash and injury hazards to the rider.The recall involves Surly 8-pack racks and Surly 24-pack front bicycle racks and Pack Rat bicycles.
Follow RTT
>